Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13746571 | 0.77 | ALDH1A1 (0.40) | ALDH1A1TSHRHSD17B10 | |
| SCHEMBL4248949 | 0.77 | ALDH1A1 (0.40) | ALDH1A1TSHRHSD17B10 | |
| SCHEMBL4242318 | 0.71 | ALDH1A1 (0.38) | ALDH1A1TSHRHSD17B10TDP1 | |
| SCHEMBL6899857 | 0.69 | ALDH1A1 (0.45) | ALDH1A1TSHRHSD17B10TDP1 | |
| SCHEMBL8884478 | 0.69 | ALDH1A1 (0.45) | ALDH1A1TSHRHSD17B10TDP1 | |
| SCHEMBL8884473 | 0.69 | ALDH1A1 (0.45) | ALDH1A1TSHRHSD17B10TDP1 | |
| SCHEMBL1331774 | 0.61 | — | — | |
| SCHEMBL9866292 | 0.61 | — | — | |
| SCHEMBL523 | 0.61 | — | — | |
| SCHEMBL1331977 | 0.61 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120329731-A1 | THERAPEUTIC METHODS, COMPOSITIONS, AND COMPOUNDS | NAGASAWA HERBERT T (US) | 2012-12-27 | — | — | US | disclosed |
| US-20090197865-A1 | THERAPEUTIC METHODS, COMPOSITIONS AND COMPOUNDS | REGENTS OF THE UNIVERSITY OF MINNESOTA | 2009-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120329731-A1 | THERAPEUTIC METHODS, COMPOSITIONS, AND COMPOUNDS | PC, ME3, PYGL | ALDH1A1 509/4885TSHR 3154/4885HSD17B10 1734/4885 |
| US-20090197865-A1 | THERAPEUTIC METHODS, COMPOSITIONS AND COMPOUNDS | PC, ME3, PYGL | ALDH1A1 510/4885TSHR 2984/4885HSD17B10 1565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.